Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study

Published:2019-06-05 Issue:1 Volume:50 Page:40-53
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Amiot Aurelien¹^ORCID,Serrero Melanie²,Peyrin-Biroulet Laurent³^ORCID,Filippi Jerome⁴,Pariente Benjamin⁵^ORCID,Roblin Xavier⁶^ORCID,Buisson Anthony⁷^ORCID,Stefanescu Carmen⁸,Trang-Poisson Caroline⁹^ORCID,Altwegg Romain¹⁰,Marteau Philippe¹¹,Vaysse Thibaud¹²,Bourrier Anne¹¹,Nancey Stephane¹³,Laharie David¹⁴^ORCID,Allez Matthieu¹¹^ORCID,Savoye Guillaume¹⁵,Moreau Jacques¹⁶,Vuitton Lucine¹⁷,Viennot Stephanie¹⁸,Bouguen Guillaume¹⁹^ORCID,Abitbol Vered¹¹,Fumery Mathurin²⁰^ORCID,Gagniere Charlotte¹,Bouhnik Yoram⁸,

Affiliation:

1. Creteil France

2. Marseille France

3. Nancy France

4. Nice France

5. Lille France

6. Saint-Etienne France

7. Clermont-Ferrand France

8. Clichy France

9. Nantes France

10. Montpellier France

11. Paris France

12. Kremlin Bicêtre France

13. Lyon France

14. Bordeaux France

15. Rouen France

16. Toulouse France

17. Besançon France

18. Caen France

19. Rennes France

20. Amiens France

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15294/fullpdf

Reference27 articles.

1. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease;Fiorino;Expert Rev Clin Immunol,2010

2. Review article: anti-adhesion therapies for inflammatory bowel disease;Lobaton;Aliment Pharmacol Ther,2014

3. Vedolizumab as induction and maintenance therapy for ulcerative colitis;Feagan;N Engl J Med,2013

4. Vedolizumab as induction and maintenance therapy for Crohn’s disease;Sandborn;N Engl J Med,2013

5. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed;Sands;Gastroenterology,2014

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute interstitial nephritis in patients with inflammatory bowel disease treated with vedolizumab: a systematic review;Scandinavian Journal of Gastroenterology;2024-04-29

2. Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease;Medicina;2024-02-09

3. Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis;Therapeutic Advances in Gastroenterology;2024-01

4. Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study;Crohn's & Colitis 360;2024-01-01

5. Clinical profiles and outcomes in patients with ulcerative colitis receiving standard and higher-than-standard doses of vedolizumab: findings from a real-world study in Europe;Current Medical Research and Opinion;2023-08-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3